Abstract
There is a need for effective medications to treat patients living with schizophrenia or bipolar I disorder (BD-I). LYBALVI®, a combination of olanzapine and samidorphan, was recently approved for the treatment of adults with schizophrenia or BD-I. We estimated the budgetary impact of adding LYBALVI to the formulary from Commercial, Medicaid, and Medicare perspectives in the United States (US).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
